ライフサイエンスコーパス: intraventricular

1 eurologic effects, such as ventriculomegaly, intraventricular adhesions, subependymal cysts, intracer

2 The aim is to review the role of intraventricular administration of antimicrobial agents

3 Intraventricular administration of antimicrobials may be

4 Here we show that intraventricular administration of EGF and albumin augme

5 e to seizure-induced hippocampal damage, and intraventricular administration of leptin protects neuro

6 Consistent with this finding, intraventricular administration of melanotan-2, an analo

7 In addition, intraventricular administration of VEGFB restored neurog

8 e the potential differences between chronic, intraventricular and intraputamenal (or intranigral) del

9 Intraventricular anti-miR-155 treatment derepressed micr

10 This article discusses indications for intraventricular antimicrobial agents, choice of antibio

11 Intraventricular baclofen pretreatment in rats subjected

12 Contractility was monitored by intraventricular balloon, energetics by (31)P nuclear MR

13 Using a Langendorff perfusion model and an intraventricular balloon, we subjected hearts to 20 minu

14 tfeeding < 3 months, artificial ventilation, intraventricular bleeding, and other perinatal adverse e

15 oid (Hijdra Sum Score 17 vs 14, p<0.001) and intraventricular blood (median IVH sum score 2 vs 1, p<0

16 h poor clinical grade, more subarachnoid and intraventricular blood seen on admission computed tomogr

17 hniques to remove clot, techniques to remove intraventricular blood, and management of intracranial p

18 cerebral ventricular drainage, 2) meticulous intraventricular catheter handling, 3) cerebrospinal flu

19 No evidence of intraventricular clot was found.

20 ion, cardiac arrhythmias, ventricular clots, intraventricular communications, and low blood flows.

21 In patients without AVB and no intraventricular conduction abnormalities, ventricular p

22 Compared with women with no BBB, LBBB, and intraventricular conduction defect were strong predictor

23 io, 3.53; confidence interval, 2.14-5.81 for intraventricular conduction defect).

24 LBBB, intraventricular conduction defect, and RBBB combined wi

25 and indetermined-type BBBs (LBBB, RBBB, and intraventricular conduction defect, respectively).

26 by their high voltage and are influenced by intraventricular conduction defects and acute myocardial

27 proved cardiac contractility and ameliorated intraventricular conduction defects in LmnaH222P/H222P m

28 bundle branch block (HR=1.01, P=0.975), and intraventricular conduction delay (HR=1.31, P=0.172).

29 block (RBBB) in 48 patients, and nonspecific intraventricular conduction delay (IVCD) was present in

30 ure patients with narrow QRS and nonspecific intraventricular conduction delay (NICD) display a relat

31 of death in these patients who also have an intraventricular conduction delay and are treated with C

32 n resulting from left bundle-branch block or intraventricular conduction delay but not right bundle-b

33 Left-sided intraventricular conduction delay is associated with mor

34 c imaging could be a more specific marker of intraventricular conduction delay rather than the surrog

35 of patients with left bundle branch block or intraventricular conduction delay treated with cardiac r

36 with advanced chronic heart failure (HF) and intraventricular conduction delay treated with optimal p

37 ficant factors, left bundle-branch block and intraventricular conduction delay were associated with a

38 (LBBB; including right bundle branch block, intraventricular conduction delay) did not have clinical

39 in about 70% of HF patients with left-sided intraventricular conduction delay, a fact that would exp

40 atients with symptomatic heart failure (HF), intraventricular conduction delay, and malignant ventric

41 Over half the affected cohort (28/52) had intraventricular conduction delay, or incomplete right b

42 en applied to children and young adults with intraventricular conduction delay, such as bundle branch

43 ents with poor left ventricular function and intraventricular conduction delay.

44 for an ICD who also have symptomatic HF and intraventricular conduction delay.

45 therapy for patients with heart failure and intraventricular conduction delay.

46 s in patients with heart failure who have an intraventricular conduction delay.

47 have moderate-to-severe heart failure and an intraventricular conduction delay.

48 icular ejection fraction of 35% or less, and intraventricular conduction delays (QRS > 120 ms), altho

49 for patients with advanced heart failure and intraventricular conduction delays and ventricular dyssy

50 ong patients with advanced heart failure and intraventricular conduction delays, but the cost effecti

51 ents with advanced chronic heart failure and intraventricular conduction delays.

52 block (LBBB), and in 15, it was nonspecific intraventricular conduction disturbance (NICD).

53 BB QRS pattern (right bundle-branch block or intraventricular conduction disturbances).

54 branch block, and 308 (17%) with nonspecific intraventricular conduction disturbances.

55 ction fraction of 30% or less, and prolonged intraventricular conduction with a QRS duration of 130 m

56 ECG QRS duration, a measure of cardiac intraventricular conduction, varies approximately 2-fold

57 raction order, and entropy (E), a measure of intraventricular contraction disorder, and interventricu

58 novel indices of synchrony (S), a measure of intraventricular contraction order, and entropy (E), a m

59 Intraventricular corticosterone attenuated cocaine self-

60 te contraction, postsystolic shortening, and intraventricular delay were analyzed using 2-dimensional

61 Intraventricular delivery of EVP4593 in YAC128 mice resc

62 l 6-OHDA lesions followed 1 week later by an intraventricular dose of BMP-7.

63 ded target cytotoxic concentrations after an intraventricular dose, but lumbar CSF concentrations 2 h

64 be easily achieved in ventricular CSF after intraventricular dosing.

65 ariety of schedules either by intralumbar or intraventricular drug delivery.

66 ariety of schedules either by intralumbar or intraventricular drug delivery.

67 ariety of schedules either by intralumbar or intraventricular drug delivery.

68 Patients with intraventricular dyssynchrony on echocardiography were r

69 is characteristic for LBBB and results from intraventricular dyssynchrony.

70 re at the scene (p = .045), greater rates of intraventricular extension (p < .0001), and radiologic s

71 Scale (NIHSS) score, larger ICH, presence of intraventricular extension and use of proxy responders.

72 oedema with increased intracranial pressure, intraventricular extension of haemorrhage with hydroceph

73 BACKGROUND AND Intraventricular extension of intracerebral haemorrhage

74 Intraventricular extension of intracerebral haemorrhage

75 Intraventricular extension of intracerebral hemorrhage (

76 (modified Rankin Scale score, 3-6), any new intraventricular extension or an increase in the modifie

77 igher diastolic blood pressure at the scene, intraventricular extension, and radiologically evident h

78 IVH treatment by intraventricular fibrinolysis (IVF) was recently linked

79 , hypertrophy-related fetal gene expression, intraventricular fibrosis, cardiac apoptosis, and oxidat

80 his study sought to understand the impact of intraventricular flow patterns on filling and to assess

81 Intraventricular fluid dynamics can be assessed clinical

82 Thus, intraventricular fluid mechanics are an important determ

83 atients, designated PRE based on a decreased intraventricular gradient during exercise.

84 ients had no obstruction and 38 exhibited an intraventricular gradient, 9 of whom exhibited a decreas

85 paradoxical situations in which significant intraventricular gradients (>50 mm Hg) at rest occur in

86 oor outcome, but the significance of delayed intraventricular haemorrhage (dIVH) is less well defined

87 oor outcome, but the significance of delayed intraventricular haemorrhage (dIVH) is less well defined

88 eline and 24 h CTs, with dIVH defined as new intraventricular haemorrhage (IVH) on the latter scan.

89 icular haemorrhage volume (IVH) with/without intraventricular haemorrhage (IVH) over 24 h were estima

90 te primary outcome of neonatal death, severe intraventricular haemorrhage (IVH), and periventricular

91 ntracerebral haemorrhage of 10-100 mL and no intraventricular haemorrhage admitted within 48 h of ict

92 INTERPRETATION: In patients with intraventricular haemorrhage and a routine extraventricu

93 d in all stuporous or comatose patients with intraventricular haemorrhage and acute hydrocephalus.

94 Intraventricular haemorrhage is a major complication of

95 Intraventricular haemorrhage is a subtype of intracerebr

96 As intraventricular haemorrhage leads to an inflammatory re

97 cerebral haemorrhage volume less than 30 mL, intraventricular haemorrhage obstructing the 3rd or 4th

98 stently higher in the forebrain of pups with intraventricular haemorrhage relative to pups without in

99 mine whether a greater frequency of complete intraventricular haemorrhage removal via alteplase produ

100 29], p=0.420) was found after adjustment for intraventricular haemorrhage size and thalamic intracere

101 5% CI 1.2 to 3.5; p=0.01) and higher SAH and intraventricular haemorrhage sum scores (OR 1.05, 95% CI

102 c regression, and (2) of increased haematoma+intraventricular haemorrhage volume (IVH) with/without i

103 Intraventricular haemorrhage was diagnosed by head ultra

104 atic measurement methods; shape, density and intraventricular haemorrhage were also assessed.

105 The pups with intraventricular haemorrhage were treated with inhibitor

106 To this end, we used our rabbit model of intraventricular haemorrhage where premature pups, deliv

107 e aimed to test whether attempting to remove intraventricular haemorrhage with alteplase versus salin

108 ase-2 in the inflammatory cascade induced by intraventricular haemorrhage, and cyclooxygenase-2-inhib

109 le score, increasing ICH volume, presence of intraventricular haemorrhage, and deep/infratentorial IC

110 rtality, bronchopulmonary dysplasia, sepsis, intraventricular haemorrhage, periventricular leukomalac

111 uperficial intracerebral haemorrhage without intraventricular haemorrhage.

112 ricular haemorrhage relative to pups without intraventricular haemorrhage.

113 brain damage initiated by the development of intraventricular haemorrhage.

114 izing brain damage in premature infants with intraventricular haemorrhage.

115 els were comparable in pups with and without intraventricular haemorrhage.

116 d gliosis around the ventricles of pups with intraventricular haemorrhage.

117 CNS due to repeated chronic subarachnoid or intraventricular haemorrhage.

118 Exclusion criteria were pure intraventricular haemorrhage; intracerebral haemorrhage

119 pro-inflammatory cytokines were elevated in intraventricular haemorrhage; whether their suppression

120 eath, chronic lung disease, neonatal sepsis, intraventricular hemorrhage >grade 2, periventricular le

121 8.3%), respiratory distress syndrome (8.3%), intraventricular hemorrhage (1.4%), intrauterine fetal d

122 al, 76.3; medical, 6.17), sepsis (2.66), and intraventricular hemorrhage (1.97) (P < 0.005).

123 8%] vs 13 of 103 12.6%]; P = .04) and severe intraventricular hemorrhage (11 infants [10.3%] vs 23 [2

124 5.3% [95% CI, 14.4%-16.3%]), death or severe intraventricular hemorrhage (17.5% [95% CI, 16.5%-18.6%]

125 Less platelet activity was associated with intraventricular hemorrhage (516.5 [interquartile range

126 ce of necrotizing enterocolitis, sepsis, and intraventricular hemorrhage (all grades).

127 fants of women receiving ANS included severe intraventricular hemorrhage (aRR = 0.68; 95% CI, 0.58-0.

128 Low-grade germinal matrix-intraventricular hemorrhage (GM-IVH) is the most common

129 s were categorized into three classes: 1) no intraventricular hemorrhage (grade 0); 2) mild-moderate

130 cular hemorrhage (grade 0); 2) mild-moderate intraventricular hemorrhage (grades 1-2, i.e., germinal

131 lar dilatation, respectively); and 3) severe intraventricular hemorrhage (grades 3-4, i.e., intravent

132 Thrombocytopenia and intraventricular hemorrhage (IVH) are common among very-

133 Intraventricular hemorrhage (IVH) in premature infants r

134 Intraventricular hemorrhage (IVH) in preterm infants lea

135 Intraventricular hemorrhage (IVH) is a major complicatio

136 Intraventricular hemorrhage (IVH) is a negative prognost

137 Intraventricular hemorrhage (IVH) remains a major cause

138 Intraventricular hemorrhage (IVH) results in neural cell

139 ventricles due to CSF accumulation following intraventricular hemorrhage (IVH), is a common disease u

140 ICH volume (p = 0.025), intraventricular hemorrhage (p = 0.019), presence of mic

141 rophylactic indomethacin may decrease Severe Intraventricular Hemorrhage (SIVH).

142 et function on admission are associated with intraventricular hemorrhage and death after ICH.

143 The risk of death or severe intraventricular hemorrhage and death or necrotizing ent

144 es is uniquely associated with both neonatal intraventricular hemorrhage and death.

145 th or chronic lung disease as well as severe intraventricular hemorrhage and periventricular leukomal

146 d placebo groups in the overall incidence of intraventricular hemorrhage and periventricular leukomal

147 nitric oxide had a lower incidence of severe intraventricular hemorrhage and periventricular leukomal

148 Perinatal asphyxia, intraventricular hemorrhage and stroke are common causes

149 Acute intracranial hemorrhage and intraventricular hemorrhage are devastating disorders.

150 l-age infants with low-grade periventricular-intraventricular hemorrhage are not significantly differ

151 arly-onset sepsis and severe periventricular-intraventricular hemorrhage as compared with unexposed n

152 ed to preempt the occurrence and severity of intraventricular hemorrhage as detected by ultrasound.

153 mortality, nosocomial infection, and severe intraventricular hemorrhage but not of 28-day mortality

154 Thrombocytopenia was a risk factor for intraventricular hemorrhage during the first 7 days of l

155 Detection of intraventricular hemorrhage during the first postnatal d

156 severe neonatal brain injury, defined as an intraventricular hemorrhage grade of 3 or greater or cys

157 or severe neonatal morbidity, defined as an intraventricular hemorrhage grade of 3 or greater, cysti

158 Early bedside detection of intraventricular hemorrhage holds promise for advancing

159 njection of thrombin (20U) was used to model intraventricular hemorrhage in adult rats.

160 rain activity that preempt the occurrence of intraventricular hemorrhage in extremely preterm infants

161 premature ovine fetuses and the incidence of intraventricular hemorrhage in premature infants.

162 The etiology of intraventricular hemorrhage in preterm infants is multif

163 ns between sodium intake, hypernatremia, and intraventricular hemorrhage in preterm infants.

164 The cause of intraventricular hemorrhage in term neonates is poorly u

165 roencephalography preempts the occurrence of intraventricular hemorrhage in the extremely preterm.

166 m appears to be a modifiable risk factor for intraventricular hemorrhage in very low birth weight inf

167 ompared with no abnormality, germinal matrix/intraventricular hemorrhage increased risk for current m

168 Diagnostic discrimination of intraventricular hemorrhage infants using measures of bu

169 f electroencephalography bursts found in the intraventricular hemorrhage infants were significantly s

170 Intraventricular hemorrhage is a common neurologic compl

171 Low-grade periventricular-intraventricular hemorrhage is a common neurologic morbi

172 he management of intracranial hemorrhage and intraventricular hemorrhage is complex.

173 Early bedside detection of intraventricular hemorrhage is crucial to enabling timel

174 RD, -0.14 [95% CI, -0.25 to -0.04]) and for intraventricular hemorrhage of all grades (RR, 0.62 [95%

175 gorized as either (1) germinal matrix and/or intraventricular hemorrhage or (2) parenchymal lesions a

176 ecrotizing enterocolitis or death and severe intraventricular hemorrhage or death.

177 r absence of chronic lung disease and severe intraventricular hemorrhage or periventricular leukomala

178 Chronic lung disease and severe intraventricular hemorrhage or periventricular leukomala

179 hopulmonary dysplasia (BPD), periventricular/intraventricular hemorrhage or periventricular leukomala

180 cance of intracranial hypertension in severe intraventricular hemorrhage requiring extraventricular d

181 Patients with intracranial hemorrhage and intraventricular hemorrhage should be cared for in an in

182 Term neonates with intraventricular hemorrhage should undergo neuroimaging

183 rainage placement ipsilateral to the largest intraventricular hemorrhage volume (p=.001), but not wit

184 mained significantly associated with initial intraventricular hemorrhage volume (p=.002) and extraven

185 20 mm Hg), both intracerebral hemorrhage and intraventricular hemorrhage volume, and pulse pressure.

186 Hg and initial intracerebral hemorrhage and intraventricular hemorrhage volumes were independent pre

187 Severe intraventricular hemorrhage was 7.2% in RNE hospitals an

188 Grade II to IV intraventricular hemorrhage was associated with increase

189 New or increased intraventricular hemorrhage was observed in 18% (8 of 45

190 The association of high sodium intake with intraventricular hemorrhage was of similar magnitude to

191 ys or younger and participants with isolated intraventricular hemorrhage were excluded.

192 traventricular hemorrhage (grades 3-4, i.e., intraventricular hemorrhage with ventricular dilatation

193 es 1-2, i.e., germinal matrix hemorrhages or intraventricular hemorrhage without ventricular dilatati

194 stay mortality, 12.9% (9278/71,936); severe intraventricular hemorrhage, 7.6% (4842/63,525); and inf

195 eonates of at least 36 weeks' gestation with intraventricular hemorrhage, 9 (31%) had cerebral sinove

196 ventricular drainage in patients with severe intraventricular hemorrhage, although intracranial press

197 severe retinopathy of prematurity and severe intraventricular hemorrhage, and 8 years to achieve the

198 nimally invasive interventions, clearance of intraventricular hemorrhage, and adequate blood pressure

199 ibutor to the risk of death, death or severe intraventricular hemorrhage, and death or necrotizing en

200 ly lower rates of necrotizing enterocolitis, intraventricular hemorrhage, and need for supplemental o

201 Intracerebral hemorrhage, intraventricular hemorrhage, and perihematomal edema vol

202 tatus, loss of consciousness, aneurysm size, intraventricular hemorrhage, and rebleeding), the SAH Ph

203 Hematoma expansion, intraventricular hemorrhage, and reversal of anticoagula

204 prematurity, bronchopulmonary dysplasia, and intraventricular hemorrhage, as well as death.

205 ith substantial neonatal morbidities such as intraventricular hemorrhage, bronchopulmonary dysplasia,

206 following adverse outcomes: grade III or IV intraventricular hemorrhage, cystic periventricular leuk

207 Coma Scale, intracerebral hemorrhage volume, intraventricular hemorrhage, infratentorial hemorrhage,

208 cTI elevation included poor clinical grade, intraventricular hemorrhage, loss of consciousness at ic

209 h, severe retinopathy of prematurity, severe intraventricular hemorrhage, necrotizing enterocolitis,

210 seizure, cardiomyopathy, periventricular or intraventricular hemorrhage, necrotizing enterocolitis,

211 CLD alone, death alone, air leakage, severe intraventricular hemorrhage, neurodevelopmental impairme

212 two points; infratentorial PICH, two points; intraventricular hemorrhage, one point; PICH volume grea

213 enterocolitis, sepsis, chronic lung disease, intraventricular hemorrhage, or cholestasis.

214 h by 18 to 22 months; hospital death; death, intraventricular hemorrhage, or periventricular leukomal

215 syndrome, bronchopulmonary dysplasia, severe intraventricular hemorrhage, periventricular leukomalaci

216 severe complications (defined as high-grade intraventricular hemorrhage, surgery for abdominal compl

217 Low-grade periventricular-intraventricular hemorrhage.

218 ms leading to poor outcomes in patients with intraventricular hemorrhage.

219 days after birth; and severe (grade 3 or 4) intraventricular hemorrhage.

220 elial cell wall, thereby preventing neonatal intraventricular hemorrhage.

221 consequences of intracranial hemorrhage and intraventricular hemorrhage.

222 he acute care of intracranial hemorrhage and intraventricular hemorrhage.

223 ns between sodium intake, hypernatremia, and intraventricular hemorrhage.

224 activity prior to ultrasound confirmation of intraventricular hemorrhage.

225 ; p < 0.015) than in preterm infants without intraventricular hemorrhage.

226 itis, retinopathy of prematurity, and severe intraventricular hemorrhage.

227 ounts were not significantly associated with intraventricular hemorrhage.

228 on, necrotic foci, periventricular cysts and intraventricular hemorrhages were observed distal to sta

229 apy, we conducted the first phase 1 study of intraventricular immunochemotherapy in patients with rec

230 uated antincociceptive responses produced by intraventricular improgan.

231 Intraventricular infusion of 5HT2C agonist or antagonist

232 In contrast, intraventricular infusion of a soluble form of the Nogo

233 suppressed NO production in the rat brain by intraventricular infusion of an NO synthase inhibitor.

234 ately followed by 3 or 14 days of continuous intraventricular infusion of either human recombinant de

235 We report that intraventricular infusion of ganglioside GM1 induces pho

236 idine at the midpoint of 2 weeks of conjoint intraventricular infusion of glial cell line-derived tro

237 Intraventricular infusion of Shh and a Shh receptor inhi

238 Intraventricular infusion of sNgR for 1 month results in

239 Intraventricular infusion of ss-siRNA produced selective

240 d in R6/2 mice treated only with AdBDNF, and intraventricular infusion of the mitotic inhibitor Ara-C

241 This was followed by intraventricular infusion of the MMP inhibitor FN-439 (2

242 celerates their degeneration whereas chronic intraventricular infusion of trophic factors extends the

243 In the current study, rats were given intraventricular infusions of the immunotoxin OX7-sapori

244 Intraventricular injected AFSC that homed within the glo

245 ide in the subventricular zone of the brain, intraventricular injection has been used as an administr

246 Intraventricular injection of 15d-Delta(12,14)-prostagla

247 tensive rats (SHRs) for 40 days, followed by intraventricular injection of 25 ng of Ang II.

248 re, by inhibiting SDF1 signaling in utero by intraventricular injection of a receptor antagonist, we

249 memory deficits in wild type mice induced by intraventricular injection of Abeta4-42.

250 Intraventricular injection of an MrgA1 ligand increased

251 y neurons in the mouse neocortex by in utero intraventricular injection of enhanced green fluorescent

252 Second, intraventricular injection of HA oligosaccharide reduced

253 sistant to the excitotoxic damage induced by intraventricular injection of kainic acid.

254 ic responses of rodents to the peripheral or intraventricular injection of many individual neurotrans

255 Here we show the striking finding that intraventricular injection of the high-affinity Zn2+ che

256 We previously found that although intraventricular injection of the neonatal mouse brain w

257 Intraventricular injection of tPA or active PDGF-CC, in

258 Within 15 to 30 min following intraventricular injection, there is only diffuse, non-s

259 dogenous choroid plexus epithelium following intraventricular injection.

260 ne transfer to the subventricular zone after intraventricular injection.

261 ctions of 5-bromo-2'-deoxyuridine (BrdU) and intraventricular injections of replication-deficient ret

262 at diet was blocked in ad-lib fed rats given intraventricular insulin or leptin throughout training a

263 toxicity, pharmacokinetics, and dosimetry of intraventricular iodine-131-labeled monoclonal antibody

264 Improgan (60, 100 and 140 microg, intraventricular [ivt]) elicited significant decreases i

265 atrioventricular, interventricular, and left intraventricular levels.

266 ow that there is a finite risk of forming an intraventricular mass, presumably from the cellular debr

267 significantly reduced LV volume indices and intraventricular mechanical delay, and improved LV eject

268 1 +/- 29 ms to 202 +/- 39 ms, p < 0.001) and intraventricular mechanical dyssynchrony (15 +/- 26 ms t

269 e 2.5 g/m(2), vincristine, procarbazine, and intraventricular methotrexate (12 mg).

270 Intraventricular NPQ/spexin and NPQ 53-70 also produced

271 tissue Doppler imaging techniques to assess intraventricular opposing wall delay or dispersion of ti

272 nd other adverse outcomes after placement of intraventricular or interventricular stents for this ind

273 f the ventricular system, presence of raised intraventricular pressure and topographic relationships

274 of systolic LV function such as the ejection intraventricular pressure difference (EIVPD) and the sys

275 The Doppler-derived peak ejection intraventricular pressure difference should be preferred

276 oninvasive indices tested, the peak ejection intraventricular pressure difference showed the best cor

277 ion analyses demonstrated that peak ejection intraventricular pressure difference was less sensitive

278 s color M-mode Doppler (CMM) can quantify LV intraventricular pressure gradients (IVPGs).

279 Favorable vortical effects on intraventricular pressure gradients were observed in the

280 In contrast, application of short-lived intraventricular pressure surges neither triggers PVEM n

281 V free wall and simultaneous measurements of intraventricular pressure, volume, maximal elastance (e(

282 V free wall and simultaneous measurements of intraventricular pressure, volume, maximal elastance (Em

283 tly using MRI with simultaneous recording of intraventricular pressures.

284 We conclude that intraventricular rituximab in combination with MTX is fe

285 Phase I study showed that intraventricular rituximab plus methotrexate is feasible

286 KEY POINTS: Phase I study showed that intraventricular rituximab plus methotrexate is feasible

287 Fourteen patients received 10 mg or 25 mg intraventricular rituximab twice weekly for 4 weeks, wit

288 The safety profile of intraventricular rituximab was defined in 10 patients.

289 ed a first complete response of CNS NHL with intraventricular rituximab/MTX, including 1 with CNS lym

290 alternate dosing between the intralumbar and intraventricular routes was tested.

291 as administered, alternating intralumbar and intraventricular routes.

292 rameters-namely, a low voltage and increased intraventricular septal thickness-is a useful diagnostic

293 LVID), wall thicknesses (posterior [PWT] and intraventricular septum [IVST]), and relative wall thick

294 These included intraventricular septum defects, tricuspid valve insuffi

295 Improved intraventricular synchrony during pacing also correlated

296 ynchrony) and of the LV myocardial segments (intraventricular synchrony) was observed for patients wi

297 tion of a stable scar and protection against intraventricular thrombi after acute infarction.

298 s in significant shortening of the diastolic intraventricular time delay which is closely related to

299 Intraventricular UTP injection transiently decreased blo

300 We used neonatal intraventricular viral injections to express VAPB or YFP